Stocks
Denali Therapeutics Financial Statements (DNLI) |
||||||||||
| Denali Therapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 27.02.2020 | 26.02.2021 | 28.02.2022 | 27.02.2023 | 28.02.2024 | 06.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 26.7 | 335.7 | 48.7 | 108.5 | 330.5 | 305.0 | |||
| Operating Income, bln rub | -213.2 | 62.7 | -295.8 | -340.7 | -196.7 | -504.6 | ||||
| EBITDA, bln rub | ? | -205.2 | 62.7 | -287.2 | -330.4 | -180.0 | -496.0 | |||
| Net profit, bln rub | ? | -197.6 | 71.1 | -290.6 | -326.0 | -145.2 | -427.5 | |||
| OCF, bln rub | ? | -151.6 | 416.2 | -211.4 | -244.7 | -358.0 | -362.6 | |||
| CAPEX, bln rub | ? | 17.9 | 3.10 | 8.50 | 17.8 | 12.9 | 13.1 | |||
| FCF, bln rub | ? | -169.5 | 413.1 | -219.9 | -262.5 | -370.9 | -375.7 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 239.9 | 272.9 | 344.4 | 449.2 | 527.2 | 498.3 | ||||
| Cost of production, bln rub | 193.4 | 212.6 | 5.61 | 7.03 | 423.9 | 6.28 | ||||
| R&D, bln rub | 193.4 | 212.6 | 265.4 | 358.7 | 423.9 | 404.5 | ||||
| Interest expenses, bln rub | 15.2 | 0.000 | 0.000 | 14.8 | 0.000 | 21.1 | ||||
| Assets, bln rub | 553.2 | 1 604 | 1 404 | 1 460 | 1 154 | 1 454 | ||||
| Net Assets, bln rub | ? | 394.9 | 1 151 | 962.3 | 1 042 | 1 031 | 1 318 | |||
| Debt, bln rub | 68.9 | 64.2 | 58.6 | 60.4 | 52.2 | 52.5 | ||||
| Cash, bln rub | 415.4 | 1 470 | 865.4 | 1 336 | 1 035 | 836.6 | ||||
| Net debt, bln rub | -346.5 | -1 406 | -806.9 | -1 276 | -982.3 | -784.0 | ||||
| Ordinary share price, rub | 17.4 | 83.8 | 44.6 | 27.8 | 21.5 | 19.6 | ||||
| Number of ordinary shares, mln | 95.6 | 109.0 | 121.5 | 125.5 | 137.4 | 169.5 | ||||
| Market cap, bln rub | 1 665 | 9 128 | 5 420 | 3 491 | 2 948 | 3 323 | ||||
| EV, bln rub | ? | 1 319 | 7 722 | 4 613 | 2 215 | 1 966 | 2 539 | |||
| Book value, bln rub | 395 | 1 151 | 962 | 1 042 | 1 031 | 1 318 | ||||
| EPS, rub | ? | -2.07 | 0.65 | -2.39 | -2.60 | -1.06 | -2.52 | |||
| FCF/share, rub | -1.77 | 3.79 | -1.81 | -2.09 | -2.70 | -2.22 | ||||
| BV/share, rub | 4.13 | 10.6 | 7.92 | 8.30 | 7.50 | 7.78 | ||||
| EBITDA margin, % | ? | -769.1% | 18.7% | -590.1% | -304.6% | -54.4% | -162.6% | |||
| Net margin, % | ? | -740.7% | 21.2% | -597.2% | -300.6% | -43.9% | -140.1% | |||
| FCF yield, % | ? | -10.2% | 4.53% | -4.06% | -7.52% | -12.6% | -11.3% | |||
| ROE, % | ? | -50.0% | 6.18% | -30.2% | -31.3% | -14.1% | -32.4% | |||
| ROA, % | ? | -35.7% | 4.43% | -20.7% | -22.3% | -12.6% | -29.4% | |||
| P/E | ? | -8.43 | 128.3 | -18.7 | -10.7 | -20.3 | -7.77 | |||
| P/FCF | -9.83 | 22.1 | -24.6 | -13.3 | -7.95 | -8.85 | ||||
| P/S | ? | 62.4 | 27.2 | 111.4 | 32.2 | 8.92 | 10.9 | |||
| P/BV | ? | 4.22 | 7.93 | 5.63 | 3.35 | 2.86 | 2.52 | |||
| EV/EBITDA | ? | -6.43 | 123.1 | -16.1 | -6.71 | -10.9 | -5.12 | |||
| Debt/EBITDA | 1.69 | -22.4 | 2.81 | 3.86 | 5.46 | 1.58 | ||||
| R&D/CAPEX, % | 1 079% | 6 870% | 3 122% | 2 012% | 3 276% | 3 098% | ||||
| CAPEX/Revenue, % | 67.2% | 0.92% | 17.5% | 16.4% | 3.91% | 4.28% | ||||
| Denali Therapeutics shareholders | ||||||||||
